Oppenheimer lowered the firm’s price target on Soleno Therapeutics (SLNO) to $80 from $110 and keeps an Outperform rating on the shares. The firm has revised its Soleno model to project a slower U.S. launch ramp vs. its prior estimates as well as reflect a go-it-alone scenario for European commercialization following recent management commentary. Nonetheless, Oppenheimer remains above consensus on 2026 top-line, and sees upcoming events as offering support to the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Updates Bylaws, Tightens Governance Framework
- Soleno Therapeutics management to meet with Piper Sandler
- Soleno Therapeutics Earnings Call Highlights Surging Launch
- Soleno Therapeutics price target lowered to $100 from $120 at H.C. Wainwright
- Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink